# Ashvattha Therapeutics

> Ashvattha Therapeutics is a Redwood City clinical-stage biotech developing hydroxyl dendrimer medicines that carry drugs into inflamed tissue. Its lead candidate, migaldendranib, is a subcutaneous treatment being studied for wet age-related macular degeneration and diabetic macular edema, with a goal of reducing repeat injections into the eye.

- **Founded:** 2015
- **Headquarters:** Redwood City, United States
- **Founders:** Jeffrey L. Cleland (Founder and CEO), Kannan Rangaramanujam (Co-founder; initial CTO), Sujatha Kannan (Co-founder; scientific originator)
- **Products:** Migaldendranib (MGB; D-4517.2), OP-101, 18F-OP-801, Hydroxyl dendrimer platform
- **Notable:** Reported 40-week Phase 2 migaldendranib results in 2025: annualized supplemental intravitreal injection rates fell from 8.4 to 1.6 in study eyes and from 8.3 to 0.9 in fellow eyes, versus prestudy treatment., Reported no migaldendranib treatment-related ocular or systemic serious adverse events in the 40-week Phase 2 study., Published OP-101 Phase 2a severe-COVID findings in Science Translational Medicine in 2022.

## Products & services

- **Migaldendranib (MGB; D-4517.2)** — Investigational subcutaneous hydroxyl dendrimer-conjugated VEGF receptor tyrosine kinase inhibitor for neovascular age-related macular degeneration and diabetic macular edema; Phase 2 results reported in 2025.
- **OP-101** — Investigational hydroxyl dendrimer-N-acetylcysteine conjugate studied intravenously for severe COVID-19 hyperinflammation in a Phase 2a trial.
- **18F-OP-801** — Investigational PET imaging tracer designed to visualize activated microglia and neuroinflammation.
- **Hydroxyl dendrimer platform** — Drug-delivery technology that attaches active molecules to dendrimers for selective uptake in activated cells in inflamed tissue.

## Achievements

- Reported 40-week Phase 2 migaldendranib results in 2025: annualized supplemental intravitreal injection rates fell from 8.4 to 1.6 in study eyes and from 8.3 to 0.9 in fellow eyes, versus prestudy treatment.
- Reported no migaldendranib treatment-related ocular or systemic serious adverse events in the 40-week Phase 2 study.
- Published OP-101 Phase 2a severe-COVID findings in Science Translational Medicine in 2022.
- Reported FDA alignment on the design of a planned Phase 2b/3 migaldendranib program in 2025.

## Latest updates

- **2026-01** — Named George Montgomery executive chairman as it prepared for a planned global Phase 2b/3 migaldendranib trial.
- **2025-11** — Presented 40-week Phase 2 data and FDA trial-design alignment to investor and ophthalmology audiences.
- **2025-10** — Appointed Robert J. Dempsey interim CEO and reported FDA agreement with its Phase 2b/3 trial design.
- **2025-09** — Reported topline 40-week Phase 2 results for migaldendranib in diabetic macular edema and neovascular AMD.
- **2025-06** — Presented neuroinflammation and tumor-macrophage imaging data at SNMMI.

## Links

- Website: https://avttx.com/
- LinkedIn: https://www.linkedin.com/company/ashvattha-therapeutics-inc
- Twitter/X: https://twitter.com/AshvatthaTx

---

Profile page: https://yespress.io/ashvattha-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-29